News

TB R&D Update: Researchers at EPFL create organization to help bring promising new antibiotic, ‘PBTZ169’, to market

Vadim Makarov et. al. Towards a new combination therapy for tuberculosis with next generation benzothiazinones. EMBO Molecular Medicine. 2014. March 1; 6(3). doi: 10.1002/emmm.201303575

A new antibiotic, labeled ‘PBTZ169’, has been shown to be effective against drug sensitive and MDR-tuberculosis by researchers at EPFL and the Bach Institute in Moscow. In a paper published in EMBO Molecular Medicine, researchers showed that PBTZ169 inhibited DprE1, an essential enzyme in cell wall biosynthesis. Furthermore, combination treatment of PBTZ169 with BDQ and pyrazinamide was shown to be more efficacious than the standard treatment for tuberculosis in a mouse model.

Following the publication of PBTZ169, researchers set up Innovative Medicines for Tuberculosis (iM4TB), an organization whose mission is to help usher the new antibiotic to market. Clinical trials of PBTZ169 are scheduled to begin in 2015. For more information on iM4TB visit http://im4tb.org/.

Additional Coverage and Links

EPFL sets up foundation to release antibiotic for tuberculosis

http://im4tb.org/

http://www.newtbdrugs.org/project.php?id=145554

Additional TB R&D News

Time-Dependent Diaryl Ether Inhibitors of InhA: Structure–Activity Relationship Studies of Enzyme Inhibition, Antibacterial Activity, and in vivo Efficacy

More News
30 Mar 2021
Médecins Sans Frontières (MSF) published a press release on World TB Day 2021 announcing their clinical trial, TB-Practecal , investigating novel treatment for MDR-TB has stopped enrolling earlier than originally planned due to promising results. The trial's independent data safety and monitoring...
3 Feb 2021
Last week, the World Health Organization (WHO) held a consultation to discuss the definition of extensively drug resistant (XDR) tuberculosis. The meeting was held to discuss novel treatment regimens and diagnostics for drug-resistant TB and determine its impact on the definition of XDR-TB. The...
10 Dec 2020
The Stop TB Partnership Working Group on New TB Vaccines (WGNV), Working Group on New TB Drugs (WGND), and New Diagnostics Working Group (NDWG) are developing an online course specifically designed for advocates and affected communities to provide a base of knowledge in TB research and to generate...